Everolimus (RAD001) in Tuberous Sclerosis Complex (TSC)—The EXIST Program
What is the EXIST clinical trial Program?
Novartis has initiated the EXIST (EXamining everolimus In a Study of TSC ) program to evaluate everolimus (RAD001) in tuberous sclerosis complex (TSC).
Currently, the EXIST clinical trial program comprises:
EXIST-2 (To find out more about this TSC clinical trial, click here)
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
Disclaimer : This is a global web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain program information that is different from where you practice. Please contact your local Novartis representative for the latest information specific to your country.
EXIST-2 (To find out more about this TSC clinical trial,